home / stock / achn / achn quote
Last: | $ |
---|---|
Change Percent: | -0.32% |
Open: | $6.19 |
Close: | $6.15 |
High: | $6.22 |
Low: | $6.15 |
Volume: | 1,182,135 |
Last Trade Date Time: | 12/05/2019 04:21:24 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $6.19 | $6.15 | $6.22 | $6.15 | 1,182,135 | 12-05-2019 |
$ | $6.22 | $6.17 | $6.25 | $6.16 | 1,246,038 | 12-04-2019 |
$ | $6.18 | $6.21 | $6.25 | $6.15 | 1,687,245 | 12-03-2019 |
$ | $6.23 | $6.18 | $6.23 | $6.16 | 1,110,755 | 12-02-2019 |
$ | $6.21 | $6.21 | $6.23 | $6.15 | 985,092 | 11-29-2019 |
$ | $6.19 | $6.19 | $6.20 | $6.15 | 604,208 | 11-28-2019 |
$ | $6.19 | $6.19 | $6.20 | $6.15 | 604,205 | 11-27-2019 |
$ | $6.21 | $6.17 | $6.21 | $6.15 | 1,026,329 | 11-26-2019 |
$ | $6.19 | $6.20 | $6.25 | $6.18 | 1,506,259 | 11-25-2019 |
$ | $6.18 | $6.20 | $6.20 | $6.15 | 1,717,950 | 11-22-2019 |
$ | $6.18 | $6.14 | $6.25 | $6.11 | 2,426,797 | 11-21-2019 |
$ | $6.26 | $6.23 | $6.29 | $6.17 | 4,077,582 | 11-20-2019 |
$ | $6.28 | $6.275 | $6.345 | $6.24 | 2,771,587 | 11-19-2019 |
$ | $6.28 | $6.26 | $6.28 | $6.25 | 1,009,778 | 11-18-2019 |
$ | $6.39 | $6.25 | $6.39 | $6.235 | 1,426,512 | 11-15-2019 |
$ | $6.34 | $6.34 | $6.37 | $6.33 | 1,258,754 | 11-14-2019 |
$ | $6.35 | $6.33 | $6.35 | $6.30 | 2,383,347 | 11-13-2019 |
$ | $6.35 | $6.34 | $6.36 | $6.32 | 1,344,246 | 11-12-2019 |
$ | $6.34 | $6.35 | $6.37 | $6.33 | 958,549 | 11-11-2019 |
$ | $6.35 | $6.36 | $6.42 | $6.31 | 1,598,861 | 11-08-2019 |
News, Short Squeeze, Breakout and More Instantly...
When looking at biotech stocks, a big point of focus should be on the products driving revenue now or the solidity of the pipeline, which will drive revenue later. Acadia Pharmaceuticals (NASDAQ: ACAD) , Alexion Pharmaceuticals (NASDAQ: ALXN) , and Seattle Genetics (NASDAQ: SGEN) are ...
BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that its shareholders have appr...
– 2.4 g/dL mean increase in hemoglobin at 24 weeks – – Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis – - Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020 - BLUE BELL, Pa., Dec....